PL2087890T3 - Preparat o przedłużonym uwalnianiu do terapii regeneracyjnej tkanki - Google Patents

Preparat o przedłużonym uwalnianiu do terapii regeneracyjnej tkanki

Info

Publication number
PL2087890T3
PL2087890T3 PL07830074T PL07830074T PL2087890T3 PL 2087890 T3 PL2087890 T3 PL 2087890T3 PL 07830074 T PL07830074 T PL 07830074T PL 07830074 T PL07830074 T PL 07830074T PL 2087890 T3 PL2087890 T3 PL 2087890T3
Authority
PL
Poland
Prior art keywords
sustained release
tissue regeneration
release preparation
regeneration therapy
therapy
Prior art date
Application number
PL07830074T
Other languages
English (en)
Inventor
Yoshiki Sakai
Takahiro Uchida
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of PL2087890T3 publication Critical patent/PL2087890T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL07830074T 2006-10-19 2007-10-18 Preparat o przedłużonym uwalnianiu do terapii regeneracyjnej tkanki PL2087890T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006285357 2006-10-19
PCT/JP2007/070340 WO2008047863A1 (fr) 2006-10-19 2007-10-18 Préparation à libération prolongée pour thérapie de régénération cellulaire
EP07830074.6A EP2087890B1 (en) 2006-10-19 2007-10-18 Sustained release preparation for tissue regeneration therapy

Publications (1)

Publication Number Publication Date
PL2087890T3 true PL2087890T3 (pl) 2014-08-29

Family

ID=39314081

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07830074T PL2087890T3 (pl) 2006-10-19 2007-10-18 Preparat o przedłużonym uwalnianiu do terapii regeneracyjnej tkanki

Country Status (8)

Country Link
US (1) US8617614B2 (pl)
EP (1) EP2087890B1 (pl)
JP (1) JP5423003B2 (pl)
DK (1) DK2087890T3 (pl)
ES (1) ES2459743T3 (pl)
PL (1) PL2087890T3 (pl)
PT (1) PT2087890E (pl)
WO (1) WO2008047863A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
WO2014046065A1 (ja) 2012-09-21 2014-03-27 国立大学法人大阪大学 心筋・血管再生デバイスとしての重症心不全治療材
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
WO2015056504A1 (ja) * 2013-10-15 2015-04-23 小野薬品工業株式会社 薬剤溶出性ステントグラフト
US20190343841A1 (en) * 2016-12-27 2019-11-14 Osaka University Medicinal Composition for Treating Intractable Heart Disease
EP3718537A4 (en) 2017-11-27 2021-11-10 Osaka University SITE-SPECIFIC LIPOSOMAL FORMULATION
WO2020082083A1 (en) * 2018-10-19 2020-04-23 South Dakota Board Of Regents Methods and compositions for localized intraductal drug delivery to the breast and regional lymph nodes
US11717656B2 (en) * 2019-03-20 2023-08-08 Gyros ACMI Inc. Delivery of mixed phase media for the treatment of the anatomy
CN111035626B (zh) * 2019-12-24 2021-08-06 山东大学第二医院 一种载罗氟司特药物的plga生物降解缓释制剂的制备方法
CN114699535B (zh) * 2022-01-29 2024-05-03 西北工业大学 一种微凝胶包覆金属有机框架的多效协同关节润滑剂及其制备方法
US20240091163A1 (en) 2022-09-09 2024-03-21 Ricoh Company, Ltd. Sustained releasing particle and method of producing sustained releasing particle

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100191137B1 (ko) 1992-07-21 1999-06-15 사노 가즈오 옥심 유도체
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
DE69632569T2 (de) * 1995-06-09 2005-08-18 Euroceltique S.A. Formulierungen und verfahren für eine verlängerte lokalanästhesie
JP2909418B2 (ja) * 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
ES2584606T3 (es) 2002-10-10 2016-09-28 Ono Pharmaceutical Co., Ltd. Microesferas que comprenden ONO-1301
WO2004084871A1 (en) * 2003-03-26 2004-10-07 Ltt Bio-Pharma Co., Ltd. Intravenous nanoparticles for targenting drug delivery and sustained drug release

Also Published As

Publication number Publication date
US8617614B2 (en) 2013-12-31
JPWO2008047863A1 (ja) 2010-02-25
ES2459743T3 (es) 2014-05-12
DK2087890T3 (da) 2014-05-19
US20100323026A1 (en) 2010-12-23
EP2087890B1 (en) 2014-03-05
EP2087890A4 (en) 2010-10-20
EP2087890A1 (en) 2009-08-12
JP5423003B2 (ja) 2014-02-19
PT2087890E (pt) 2014-05-12
WO2008047863A1 (fr) 2008-04-24

Similar Documents

Publication Publication Date Title
EP2087890A4 (en) PREPARING WITH DELAYED RELEASE FOR TISSUE GENERATION THERAPY
EP2119444A4 (en) THERAPEUTIC AGENT FOR PAIN
EP2004809A4 (en) EX VIVO CREATED TISSUE SYSTEM
IL198663A0 (en) Tissue treatment methods
GB0609492D0 (en) Therapeutic agents
EP2005806A4 (en) SETTING PATIENTS BY TOMOSYNTHESIS TECHNIQUES
GB0608928D0 (en) Therapeutic agents
EP2117311A4 (en) THERAPEUTICS
HUE054365T2 (hu) Bór-ftalidok terápiás alkalmazásra
GB0601962D0 (en) Therapeutic agents
HRP20130041T8 (en) Therapeutic agents
GB0616214D0 (en) Therapeutic Agents
EP1968603A4 (en) THERAPEUTIC AMINARYLSULFONAMIDE CONJUGATE COMPOUNDS
IL193597A0 (en) Conjunctival tissue system
GB0723747D0 (en) Therapeutic agents
GB0611152D0 (en) Therapeutic agents
GB0620818D0 (en) Therapeutic agents
GB0620059D0 (en) Therapeutic agents
GB0609676D0 (en) Therapeutic agents
HK1131339A1 (en) Prophylactic or therapeutic agent for viral disease
EP2127658A4 (en) THERAPEUTIC AGENT AGAINST MORBUS MENIERE
EP2140876A4 (en) THERAPEUTIC AGENT COMPRISING VASOHIBINE
EP2210878A4 (en) THERAPEUTIC AGENT AGAINST TRPV1-MEDIATED DISEASES
GB0723748D0 (en) Therapeutic agents
GB0622195D0 (en) Therapeutic agents